Exhibit 10.1



 Exhibit 10.1 
 ICF INTERNATIONAL, INC. 
 3,100,000 Shares 
 Common Stock 
 ($0.001 par value per share) 
 UNDERWRITING AGREEMENT 
 December 10, 2009 







 UNDERWRITING AGREEMENT 
 December 10, 2009 
 William
Blair & Company, L.L.C. 
 Stifel, Nicolaus & Company, Incorporated 
     as Managing Underwriters 
  

	c/o	William Blair & Company, L.L.C. 


	 	222 West Adams Street 


	 	Chicago, Illinois 60606 

 Ladies and Gentlemen:

 ICF INTERNATIONAL, INC., a Delaware corporation (the “Company”), proposes to issue and sell to the
underwriters named in Schedule A annexed hereto (the “Underwriters”), for whom William Blair & Company, L.L.C. and Stifel, Nicolaus & Company, Incorporated are acting as representatives (the
“Representatives”), an aggregate of 3,100,000 shares (the “Firm Shares”) of common stock, $0.001 par value per share (the “Common Stock”), of the Company. In addition, solely for the purpose of
covering over-allotments, the Company proposes to grant to the Underwriters the option to purchase from the Company up to an additional 465,000 shares of Common Stock (the “Additional Shares”). The Firm Shares and the Additional
Shares are hereinafter collectively sometimes referred to as the “Shares.” The Shares are described in the Prospectus which is referred to below. 
 The Company has prepared and filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the “Act”), with
the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-3 (File No. 333-161896) under the Act (the “registration statement”), including a prospectus, which registration
statement incorporates by reference documents which the Company has filed, or will file, in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the
“Exchange Act”). Such registration statement has become effective under the Act. 
 Except where the context
otherwise requires, “Registration Statement,” as used herein, means the registration statement, as amended at the time of such registration statement’s effectiveness for purposes of Section 11 of the Act, as such section
applies to the respective Underwriters (the “Effective Time”), including (i) all documents filed as a part thereof or incorporated or deemed to be incorporated by reference therein, (ii) any information contained or
incorporated by reference in a prospectus filed with the Commission pursuant to Rule 424(b) under the Act, to the extent such information is deemed, pursuant to Rule 430B or Rule 430C under the Act, to be part of the registration statement at the
Effective Time, and (iii) any registration statement filed to register the offer and sale of Shares pursuant to Rule 462(b) under the Act. 
 The Company has furnished to the Representatives, for use by the Underwriters and by dealers in connection with the offering of the Shares, copies of one or more preliminary prospectus supplements, and
the documents incorporated by reference therein, relating to the

  

 1 








 
Shares. Except where the context otherwise requires, “Pre-Pricing Prospectus,” as used herein, means each such preliminary prospectus supplement, in the form so furnished,
including any basic prospectus (whether or not in preliminary form) furnished to the Representatives by the Company and attached to or used with such preliminary prospectus supplement. Except where the context otherwise requires, “Basic
Prospectus,” as used herein, means any such basic prospectus and any basic prospectus furnished to the Representatives by the Company and attached to or used with the Prospectus Supplement (as defined below). 
 Except where the context otherwise requires, “Prospectus Supplement,” as used herein, means the final prospectus
supplement, relating to the Shares, filed by the Company with the Commission pursuant to Rule 424(b) under the Act on or before the second business day after the date hereof (or such earlier time as may be required under the Act), in the form
furnished by the Company to the Representatives for use by the Underwriters and by dealers in connection with the offering of the Shares. 
 Except where the context otherwise requires, “Prospectus,” as used herein, means the Prospectus Supplement together with the Basic Prospectus. 
 “Permitted Free Writing Prospectuses,” as used herein, means the documents listed on Schedule B attached hereto and
each “road show” (as defined in Rule 433 under the Act), if any, related to the offering of the Shares contemplated hereby that is a “written communication” (as defined in Rule 405 under the Act). The Underwriters have not
offered or sold and will not offer or sell, without the Company’s consent, any Shares by means of any “free writing prospectus” (as defined in Rule 405 under the Act) that is required to be filed by the Underwriters with the
Commission pursuant to Rule 433 under the Act, other than a Permitted Free Writing Prospectus. 
 “Disclosure
Package,” as used herein, means any Pre-Pricing Prospectus or Basic Prospectus, in either case together with any combination of one or more of the Permitted Free Writing Prospectuses, if any. 
 Any reference herein to the registration statement, the Registration Statement, any Basic Prospectus, any Pre-Pricing Prospectus, the
Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus shall be deemed to refer to and include the documents, if any, incorporated by reference, or deemed to be incorporated by reference, therein (the “Incorporated
Documents”), including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms “amend,” “amendment” or
“supplement” with respect to the Registration Statement, any Basic Prospectus, any Pre-Pricing Prospectus, the Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus shall be deemed to refer to and include
the filing of any document under the Exchange Act on or after the initial effective date of the Registration Statement, or the date of such Basic Prospectus, such Pre-Pricing Prospectus, the Prospectus Supplement, the Prospectus or such Permitted
Free Writing Prospectus, as the case may be, and deemed to be incorporated therein by reference. 
 As used in this Agreement,
“business day” shall mean a day on which the New York Stock Exchange (the “NYSE”) is open for trading. The terms “herein,” “hereof,” “hereto,”

  

 2 








 
“hereinafter” and similar terms, as used in this Agreement, shall in each case refer to this Agreement as a whole and not to any particular section, paragraph, sentence or other
subdivision of this Agreement. The term “or,” as used herein, is not exclusive. 
 The Company and the Underwriters
agree as follows: 
 1. Sale and Purchase. Upon the basis of the representations and warranties and subject to the terms
and conditions herein set forth, the Company agrees to issue and sell to the respective Underwriters and each of the Underwriters, severally and not jointly, agrees to purchase from the Company the number of Firm Shares set forth opposite the name
of such Underwriter in Schedule A attached hereto, subject to adjustment in accordance with Section 8 hereof, in each case at a purchase price of $23.5162 per Share. The Company is advised by the Representatives that the Underwriters
intend (i) to make a public offering of their respective portions of the Firm Shares as soon after the effectiveness of this Agreement as in the Representatives’ judgment is advisable and (ii) initially to offer the Firm Shares upon
the terms set forth in the Prospectus. The Representatives may from time to time increase or decrease the public offering price after the public offering of the Shares to such extent as the Representatives may determine. 
 In addition, the Company hereby grants to the several Underwriters the option (the “Over-Allotment Option”) to
purchase, and upon the basis of the representations and warranties and subject to the terms and conditions herein set forth, the Underwriters shall have the right to purchase, severally and not jointly, from the Company, ratably in accordance with
the number of Firm Shares to be purchased by each of them, all or a portion of the Additional Shares as may be necessary to cover over-allotments made in connection with the offering of the Firm Shares, at the same purchase price per share to be
paid by the Underwriters to the Company for the Firm Shares. The Over-Allotment Option may be exercised by William Blair & Company, L.L.C. (“William Blair”) on behalf of the several Underwriters at any time and from time to
time on or before the thirtieth day following the date of the Prospectus Supplement, by written notice to the Company. Such notice shall set forth the aggregate number of Additional Shares as to which the Over-Allotment Option is being exercised and
the date and time when the Additional Shares are to be delivered (any such date and time being herein referred to as an “additional time of purchase”); provided, however, that no additional time of purchase shall be
earlier than the “time of purchase” (as defined below), nor earlier than the second business day after the date on which the Over-Allotment Option shall have been exercised, nor later than the tenth business day after the date on which the
Over-Allotment Option shall have been exercised. Upon any exercise of the Over-Allotment Option, and subject to such adjustment as William Blair may determine to avoid fractional shares, the number of Additional Shares to be purchased by each
Underwriter, severally and not jointly, shall be the number which bears the same proportion to the aggregate number of Additional Shares being purchased (the “Option Purchased Amount”) as the number of Firm Shares set forth opposite
the name of such Underwriter in Schedule A annexed hereto bears to the total number of Firm Shares, subject to adjustment in accordance with Section 8 hereof. 
 2. Payment and Delivery. Payment of the purchase price for the Firm Shares shall be made to the Company by Federal Funds wire
transfer against delivery of the certificates for the Firm Shares to the Representatives through the facilities of The Depository Trust Company

  

 3 








 
(“DTC”) for the respective accounts of the Underwriters. Such payment and delivery shall be made at 10:00 A.M., New York City time, on December 16, 2009 (unless another time
shall be agreed to by the Representatives and the Company or unless postponed in accordance with the provisions of Section 8 hereof). The time at which such payment and delivery are to be made is hereinafter sometimes called the “time
of purchase.” Electronic transfer of the Firm Shares shall be made to the Representatives at the time of purchase in such names and in such denominations as the Representatives shall specify. 
 Payment of the purchase price for the Additional Shares shall be made to the Company at the applicable additional time of purchase in the
same manner and at the same office as the payment for the Firm Shares. Electronic transfer of the Additional Shares shall be made to the Representatives at the additional time of purchase in such names and in such denominations as the
Representatives shall specify. 
 Deliveries of the documents described in Section 6 hereof with respect to the purchase of
the Shares shall be made at the offices of Davis Polk & Wardwell LLP at 450 Lexington Avenue, New York, New York, at 9:00 A.M., New York City time, on the date of the closing of the purchase of the Firm Shares or the Additional Shares, as
the case may be. 
 3. Representations and Warranties of the Company. The Company represents and warrants to and agrees
with each of the Underwriters that: 
 (a) the Registration Statement has heretofore become effective under the
Act or, with respect to any registration statement to be filed to register the offer and sale of Shares pursuant to Rule 462(b) under the Act, will be filed with the Commission and become effective under the Act no later than 10:00 P.M., New York
City time, on the date of determination of the public offering price for the Shares; no stop order of the Commission preventing or suspending the use of any Basic Prospectus, any Pre-Pricing Prospectus, the Prospectus Supplement, the Prospectus or
any Permitted Free Writing Prospectus, or the effectiveness of the Registration Statement, has been issued, and no proceedings for such purpose have been instituted or, to the Company’s knowledge, are contemplated by the Commission; 

(b) the Registration Statement complied when it became effective, complies as of the date hereof and, as amended or
supplemented, at the time of purchase, each additional time of purchase, if any, and at all times during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar
rule) in connection with any sale of Shares, will comply, in all material respects, with the requirements of the Act; the conditions to the use of Form S-3 in connection with the offering and sale of the Shares as contemplated hereby have been
satisfied; the Registration Statement meets, and the offering and sale of the Shares as contemplated hereby complies with, the requirements of Rule 415 under the Act (including, without limitation, Rule 415(a)(5) under the Act); the Registration
Statement did not, as of the Effective Time, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; each Pre-Pricing Prospectus
complied, at the time it was filed with the Commission, and complies as of the date hereof, in all material respects with the

  

 4 








 
requirements of the Act; at no time during the period that begins on the earlier of the date of such Pre-Pricing Prospectus and the date such Pre-Pricing Prospectus was filed with the Commission
and ends at the time of purchase did or will any Pre-Pricing Prospectus, as then amended or supplemented, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances under which they were made, not misleading, and at no time during such period did or will any Pre-Pricing Prospectus, as then amended or supplemented, together with any combination of one or more of the then issued Permitted
Free Writing Prospectuses, if any, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; each
Basic Prospectus complied or will comply, as of its date and the date it was or will be filed with the Commission, complies as of the date hereof (if filed with the Commission on or prior to the date hereof) and, at the time of purchase, each
additional time of purchase, if any, and at all times during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule) in connection with any sale of Shares,
will comply, in all material respects, with the requirements of the Act; at no time during the period that begins on the earlier of the date of such Basic Prospectus and the date such Basic Prospectus was filed with the Commission and ends at the
time of purchase did or will any Basic Prospectus, as then amended or supplemented, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading, and at no time during such period did or will any Basic Prospectus, as then amended or supplemented, together with any combination of one or more of the then issued Permitted Free Writing Prospectuses, if
any, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; each of the Prospectus Supplement
and the Prospectus will comply, as of the date that it is filed with the Commission, the date of the Prospectus Supplement, the time of purchase, each additional time of purchase, if any, and at all times during which a prospectus is required by the
Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule) in connection with any sale of Shares, in all material respects, with the requirements of the Act (in the case of the Prospectus
including, without limitation, Section 10(a) of the Act); at no time during the period that begins on the earlier of the date of the Prospectus Supplement and the date the Prospectus Supplement is filed with the Commission and ends at the later
of the time of purchase, the latest additional time of purchase, if any, and the end of the period during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar
rule) in connection with any sale of Shares did or will any Prospectus Supplement or the Prospectus, as then amended or supplemented, include an untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading; at no time during the period that begins on the date of such Permitted Free Writing Prospectus and ends at the time of purchase did or will any
Permitted Free Writing Prospectus include an untrue statement of a material fact or omit to state a material fact necessary in order to

  

 5 








 
make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that the Company makes no representation or warranty in
this Section 3(b) with respect to any statement contained in the Registration Statement, any Pre-Pricing Prospectus, the Prospectus or any Permitted Free Writing Prospectus in reliance upon and in conformity with information concerning an
Underwriter and furnished in writing by or on behalf of such Underwriter through the Representatives to the Company expressly for use in the Registration Statement, such Pre-Pricing Prospectus, the Prospectus or such Permitted Free Writing
Prospectus; each Incorporated Document, at the time such document was filed with the Commission or at the time such document became effective, as applicable, complied, in all material respects, with the requirements of the Exchange Act and did not
include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; 
 (c) prior to the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any Shares by
means of any “prospectus” (within the meaning of the Act) or used any “prospectus” (within the meaning of the Act) in connection with the offer or sale of the Shares, in each case other than the Pre-Pricing Prospectuses and the
Permitted Free Writing Prospectuses, if any; the Company has not, directly or indirectly, prepared, used or referred to any Permitted Free Writing Prospectus except in compliance with Rules 164 and 433 under the Act; assuming that such Permitted
Free Writing Prospectus is so sent or given after the Registration Statement was filed with the Commission (and after such Permitted Free Writing Prospectus was, if required pursuant to Rule 433(d) under the Act, filed with the Commission), the
sending or giving, by any Underwriter, of any Permitted Free Writing Prospectus will satisfy the provisions of Rule 164 and Rule 433 (without reliance on subsections (b), (c) and (d) of Rule 164); the conditions set forth in one or more of
subclauses (i) through (iv), inclusive, of Rule 433(b)(1) under the Act are satisfied, and the registration statement relating to the offering of the Shares contemplated hereby, as initially filed with the Commission, includes a prospectus
that, other than by reason of Rule 433 or Rule 431 under the Act, satisfies the requirements of Section 10 of the Act; neither the Company nor the Underwriters are disqualified, by reason of subsection (f) or (g) of Rule 164 under the
Act, from using, in connection with the offer and sale of the Shares, “free writing prospectuses” (as defined in Rule 405 under the Act) pursuant to Rules 164 and 433 under the Act; the Company is not an “ineligible issuer” (as
defined in Rule 405 under the Act) as of the eligibility determination date for purposes of Rules 164 and 433 under the Act with respect to the offering of the Shares contemplated by the Registration Statement; the parties hereto agree and
understand that the content of any and all “road shows” (as defined in Rule 433 under the Act) related to the offering of the Shares contemplated hereby is solely the property of the Company; 
 (d) as of the date of this Agreement, (i) the Company meets the registrant requirements, and (ii) the offer of
Shares as contemplated by this Agreement meets the transaction requirements, for the use of Form S-3 under the Act pursuant to the standards for such Form S-3 in effect prior to October 21, 1992; 
  

 6 








 (e) as of the date of this Agreement, the Company has an authorized and
outstanding capitalization as set forth in the sections of the Registration Statement, the Pre-Pricing Prospectuses and the Prospectus entitled “Capitalization” and “Description of Capital Stock” (and any similar sections or
information, if any, contained in any Permitted Free Writing Prospectus), and, as of the time of purchase and any additional time of purchase, as the case may be, the Company shall have an authorized and outstanding capitalization as set forth in
the sections of the Registration Statement, the Pre-Pricing Prospectuses and the Prospectus entitled “Capitalization” and “Description of Capital Stock” (and any similar sections or information, if any, contained in any Permitted
Free Writing Prospectus) (subject, in each case, to the issuance of shares of Common Stock upon exercise of stock options and warrants disclosed as outstanding in the Registration Statement (excluding the exhibits thereto), each Pre-Pricing
Prospectus and the Prospectus and the grant of options under existing stock option plans described in the Registration Statement (excluding the exhibits thereto), each Pre-Pricing Prospectus and the Prospectus); all of the issued and outstanding
shares of capital stock, including the Common Stock, of the Company have been duly authorized and validly issued and are fully paid and non-assessable, have been issued in compliance with all applicable securities laws and were not issued in
violation of any preemptive right, resale right, right of first refusal or similar right; the Shares are duly listed, and admitted and authorized for trading, subject to official notice of issuance, on the Nasdaq Global Select Market (the
“NASDAQ”); 
 (f) as of the date of this Agreement, there is a “bona fide public
market” (as defined in NASD Rule 2720(f)(3) of FINRA) for the Shares being offered by the Company as contemplated under this Agreement; 
 (g) as of the date of this Agreement, the Company meets the registrant requirements set forth in Rule 139 under the Act for the publishing of issuer-specific research reports; 
 (h) the Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the
State of Delaware, has requisite corporate power and authority to own, lease and operate its properties and conduct its business as described in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing
Prospectuses, if any, to execute and deliver this Agreement and to issue, sell and deliver the Shares as contemplated herein; 
 (i) the Company is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction where the ownership or leasing of its properties or the conduct of its business
requires such qualification, except where the failure to be so qualified and in good standing would not, individually or in the aggregate, either (i) have a material adverse effect on the business, properties, financial condition, results of
operations, cash flows, management or prospects of the Company and the Significant Subsidiaries (as defined below) taken as a whole, (ii) prevent or materially interfere with consummation of the transactions contemplated hereby or result in any
liability for any Underwriter or (iii) prevent the shares of Common Stock from being accepted for listing on, or result in the delisting of shares of Common Stock from NASDAQ (the occurrence

  

 7 








 
of any such effect or any such prevention or interference or any such result described in the foregoing clauses (i), (ii) and (iii) being herein referred to as a “Material
Adverse Effect”); 
 (j) the Company has no subsidiaries (as defined under the Act) other than those
(i) identified in Exhibit 21.0 to the Company’s Annual Report on Form 10-K filed on March 13, 2009, plus (ii) Macro International Inc. (“Macro”) (collectively, the “Subsidiaries”); the Company
owns all of the issued and outstanding capital stock or ownership interest of each of the domestic Subsidiaries; other than the capital stock of the Subsidiaries, the Company does not own, directly or indirectly, any shares of stock or any other
equity interests or long-term debt securities of any corporation, firm, partnership, joint venture, association or other entity; complete and correct copies of the organizational documents of the Company and each Significant Subsidiary and all
amendments thereto have been delivered to the Representatives, and no changes therein will be made on or after the date hereof through and including the time of purchase or, if later, any additional time of purchase; each Significant Subsidiary has
been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation; each Significant Subsidiary has the requisite corporate power and authority to own, lease and operate its
properties and to conduct its business as described in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any; each Significant Subsidiary is duly qualified to do business as a
foreign corporation and is in good standing in each jurisdiction where the ownership or leasing of its properties or the conduct of its business requires such qualification, except where the failure to be so qualified and in good standing would not,
individually or in the aggregate, have a Material Adverse Effect; all of the outstanding shares of capital stock or ownership interests of each of the Significant Subsidiaries have been duly authorized and validly issued, are fully paid and
non-assessable, and have been issued in compliance with all applicable securities laws, were not issued in violation of any preemptive right, resale right, right of first refusal or similar right and are owned by the Company subject to no security
interest, other encumbrance or adverse claims; no options, warrants or other rights to purchase, agreements or other obligations to issue or other rights to convert any obligation into shares of capital stock or ownership interests in the
Subsidiaries are outstanding; the Company has no “significant subsidiary,” as that term is defined in Rule 1-02(w) of Regulation S-X under the Act, other than ICF Consulting Group, Inc., ICF Incorporated, L.L.C., ICF Emergency Management
Services, LLC, and Macro (“Significant Subsidiaries”); 
 (k) the Shares have been duly and
validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued, fully paid and non-assessable and free of statutory and contractual preemptive rights, resale rights, rights of first
refusal and similar rights; the Shares, when issued and delivered against payment therefor as provided herein, will be free of any restriction upon the voting or transfer thereof pursuant to the Company’s charter or bylaws or any agreement or
other instrument to which the Company is a party; 
 (l) the capital stock of the Company, including the Shares,
conforms in all

  

 8 








 
material respects to each description thereof, if any, contained or incorporated by reference in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free
Writing Prospectuses, if any; and the certificates for the Shares are in due and proper form; 
 (m) this
Agreement has been duly authorized, executed and delivered by the Company; 
 (n) neither the Company nor any of
the Significant Subsidiaries is in breach or violation of or in default under (nor has any event occurred which, with notice, lapse of time or both, would result in any breach or violation of, constitute a default under or give the holder of any
indebtedness (or a person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a part of such indebtedness under) (A) its organizational documents, or (B) any indenture, mortgage, deed
of trust, bank loan or credit agreement or other evidence of indebtedness, or any license, lease, contract or other agreement or instrument to which it is a party or by which it or any of its properties may be bound or affected, or (C) any
federal, state, local or foreign law, regulation or rule, or (D) any rule or regulation of any self-regulatory organization or other non-governmental regulatory authority (including, without limitation, the rules and regulations of the NASDAQ),
or (E) any decree, judgment or order applicable to it or any of its properties, except in the case of clauses (B), (C), (D) and (E) above as would not, individually or in the aggregate, have a Material Adverse Effect; 
 (o) the execution, delivery and performance of this Agreement, the issuance and sale of the Shares and the consummation of
the transactions contemplated hereby will not conflict with, result in any breach or violation of or constitute a default under (nor constitute any event which, with notice, lapse of time or both, would result in any breach or violation of,
constitute a default under or give the holder of any indebtedness (or a person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a part of such indebtedness under) (or result in the creation
or imposition of a lien, charge or encumbrance on any property or assets of the Company or any Significant Subsidiary pursuant to) (A) the charter or bylaws of the Company or organizational documents of any of the Significant Subsidiaries, or
(B) any indenture, mortgage, deed of trust, bank loan or credit agreement or other evidence of indebtedness, or any license, lease, contract or other agreement or instrument to which the Company or any of the Significant Subsidiaries is a party
or by which any of them or any of their respective properties may be bound or affected, or (C) any federal, state, local or foreign law, regulation or rule, or (D) any rule or regulation of any self-regulatory organization or other
non-governmental regulatory authority (including, without limitation, the rules and regulations of the NASDAQ), or (E) any decree, judgment or order applicable to the Company or any of the Significant Subsidiaries or any of their respective
properties; 
 (p) no approval, authorization, consent or order of or filing with any federal, state, local or
foreign governmental or regulatory commission, board, body, authority or agency, or of or with any self-regulatory organization or other non-governmental regulatory authority (including, without limitation, the NASDAQ), or approval of the

  

 9 








 
stockholders of the Company, is required in connection with the issuance and sale of the Shares or the consummation by the Company of the transactions contemplated hereby, other than
(i) registration of the Shares under the Act, which has been effected (or, with respect to any registration statement to be filed hereunder pursuant to Rule 462(b) under the Act, will be effected in accordance herewith), (ii) any necessary
qualification under the securities or blue sky laws of the various jurisdictions in which the Shares are being offered by the Underwriters, (iii) any necessary listing application with the NASDAQ, or (iv) as may be required under the
Conduct Rules of NASD, as enforced by the FINRA Board of Governors; 
 (q) except as described in the
Registration Statement (excluding the exhibits thereto), each Pre-Pricing Prospectus and the Prospectus, (i) no person has the right, contractual or otherwise, to cause the Company to issue or sell to it any shares of Common Stock or shares of
any other capital stock or other equity interests of the Company, (ii) no person has any preemptive rights, resale rights, rights of first refusal or other rights to purchase any shares of Common Stock or shares of any other capital stock of or
other equity interests in the Company and (iii) no person has the right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Shares; no person has the right, contractual or otherwise, to
cause the Company to register under the Act any shares of Common Stock or shares of any other capital stock of or other equity interests in the Company, or to include any such shares or interests in the Registration Statement or the offering
contemplated thereby; 
 (r) each of the Company and the Significant Subsidiaries has all necessary licenses,
authorizations, consents and approvals and has made all necessary filings required under any applicable law, regulation or rule, and has obtained all necessary licenses, authorizations, consents and approvals from other persons, in order to conduct
their respective businesses, except where the failure to have made any such filings or obtained any such authorizations, consents and approvals would not, individually or in the aggregate, have a Material Adverse Effect; neither the Company nor any
of the Significant Subsidiaries is in violation of, or in default under, or has received notice of any proceedings relating to revocation or modification of, any such license, authorization, consent or approval or any federal, state, local or
foreign law, regulation or rule or any decree, order or judgment applicable to the Company or any of the Significant Subsidiaries, except where such violation, default, revocation or modification would not, individually or in the aggregate, have a
Material Adverse Effect; 
 (s) there are no actions, suits, claims, investigations or proceedings pending or, to
the Company’s knowledge, threatened or contemplated to which the Company or any of the Significant Subsidiaries or any of their respective directors or officers is or would be a party or of which any of their respective properties is or would
be subject at law or in equity, before or by any federal, state, local or foreign governmental or regulatory commission, board, body, authority or agency, or before or by any self-regulatory organization or other non-governmental regulatory
authority (including, without limitation, the NASDAQ), except any such action, suit, claim, investigation or proceeding which, if resolved adversely to the Company or any Significant Subsidiary, would not have a Material Adverse Effect; 

 

 10 








 (t) Grant Thornton LLP, whose report on the consolidated financial
statements of the Company and the Subsidiaries is included or incorporated by reference in the Registration Statement, the Pre-Pricing Prospectuses and the Prospectus, is an independent registered public accounting firm as required by the Act and by
the rules of the Public Company Accounting Oversight Board; KPMG LLP, whose report on the consolidated financial statements of Macro is incorporated by reference in the Registration Statement, the Pre-Pricing Prospectuses and the Prospectus, is an
independent registered public accounting firm as required by the Act and by the rules of the Public Company Accounting Oversight Board; 
 (u) the financial statements included or incorporated by reference in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, together
with the related notes and schedules, present fairly the consolidated financial position of the Company and the Subsidiaries as of the dates indicated and of Macro as of the dates indicated and the consolidated results of operations, cash flows and
changes in stockholders’ equity of the Company for the periods specified and of Macro for the periods specified and have been prepared in compliance with the requirements of the Act and Exchange Act and in conformity with U.S. generally
accepted accounting principles applied on a consistent basis during the periods involved; all pro forma financial statements or data included or incorporated by reference in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus
and the Permitted Free Writing Prospectuses, if any, comply with the requirements of the Act and the Exchange Act, and the assumptions used in the preparation of such pro forma financial statements and data are reasonable, the pro forma adjustments
used therein are appropriate to give effect to the transactions or circumstances described therein and the pro forma adjustments have been properly applied to the historical amounts in the compilation of those statements and data; the other
financial and statistical data contained or incorporated by reference in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, are accurately and fairly presented and prepared
on a basis consistent with the financial statements and books and records of the Company; there are no financial statements (historical or pro forma) that are required to be included or incorporated by reference in the Registration Statement, any
Pre-Pricing Prospectus or the Prospectus that are not included or incorporated by reference as required; the Company and the Subsidiaries do not have any material liabilities or obligations, direct or contingent (including any off-balance sheet
obligations), not described in the Registration Statement (excluding the exhibits thereto), each Pre-Pricing Prospectus and the Prospectus; and all disclosures contained or incorporated by reference in the Registration Statement, the Pre-Pricing
Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act
and Item 10 of Regulation S-K under the Act, to the extent applicable; 
 (v) subsequent to the respective
dates as of which information is given in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, in each case excluding any amendments or supplements to the foregoing made after
the execution of this Agreement, there has not

  

 11 








 
been (i) any material adverse change, or any development involving a prospective material adverse change, in the business, properties, financial condition, results of operations, cash flows,
management or prospects of the Company and the Subsidiaries taken as a whole, (ii) any transaction which is material to the Company and the Subsidiaries taken as a whole, (iii) any obligation or liability, direct or contingent (including
any off-balance sheet obligations), incurred by the Company or any Subsidiary, which is material to the Company and the Subsidiaries taken as a whole, (iv) any change in the capital stock or outstanding indebtedness of the Company or any
Subsidiaries, which is material to the Company and the Subsidiaries taken as a whole, or (v) any dividend or distribution of any kind declared, paid or made on the capital stock of the Company or any Subsidiary; 
 (w) the Company has obtained for the benefit of the Underwriters the agreement (a “Lock-Up Agreement”), in
substantially the form set forth as Exhibit A-1 hereto, of each of its directors and “officers” (within the meaning of Rule 16a-1(f) under the Exchange Act) and each beneficial owner of more than 5% of the Common Stock, in
substantially the form set forth as Exhibit A-2 hereto (the parties referred to above being identified on Exhibit A-3 attached hereto); 
 (x) neither the Company nor any Subsidiary is, and at no time during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any
similar rule) in connection with any sale of Shares will any of them be, and, after giving effect to the offering and sale of the Shares, none of them will be, an “investment company” or an entity “controlled” by an
“investment company,” as such terms are defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”); 
 (y) the Company and each of the Significant Subsidiaries have good and marketable title to all property (real and personal)
described in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, as being owned by any of them, free and clear of all liens, claims, security interests or other encumbrances,
except for liens, security interests and encumbrances described in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, and except as would not, individually or in the
aggregate, have a Material Adverse Effect; all the property described in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, as being held under lease by the Company or a
Significant Subsidiary is held thereby under valid, subsisting and enforceable leases, with such exceptions as do not, individually or in the aggregate, have a Material Adverse Effect; 
 (z) each of the Company and the Significant Subsidiaries owns or possesses all inventions, patent applications, patents,
trademarks (both registered and unregistered), tradenames, service names, copyrights, trade secrets and other proprietary information described in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free
Writing Prospectuses, if any, as being owned or licensed by it or which is necessary for the conduct of, or material to, its businesses (collectively, the

  

 12 








 
“Intellectual Property”), except where the failure to own or possess such Intellectual Property would not, individually or in the aggregate, have a Material Adverse Effect, and
the Company is unaware of any claim to the contrary or any challenge by any other person to the rights of the Company or any of the Significant Subsidiaries with respect to the Intellectual Property that, if resolved adversely to the Company, would,
individually or in the aggregate, have a Material Adverse Effect; neither the Company nor any of the Significant Subsidiaries has infringed or is infringing the intellectual property of a third party, and neither the Company nor any Significant
Subsidiary has received notice of a claim by a third party to the contrary that, if resolved adversely to the Company, would, individually or in the aggregate, have a Material Adverse Effect; 
 (aa) neither the Company nor any of the Significant Subsidiaries is engaged in any unfair labor practice; except for matters
which would not, individually or in the aggregate, have a Material Adverse Effect, (i) there is (A) no unfair labor practice complaint pending or, to the Company’s knowledge, threatened against the Company or any of the Significant
Subsidiaries before the National Labor Relations Board, and no grievance or arbitration proceeding arising out of or under collective bargaining agreements is pending or, to the Company’s knowledge, threatened, (B) no strike, labor
dispute, slowdown or stoppage pending or, to the Company’s knowledge, threatened against the Company or any of the Significant Subsidiaries and (C) no union representation dispute currently existing concerning the employees of the Company
or any of the Significant Subsidiaries, (ii) to the Company’s knowledge, no union organizing activities are currently taking place concerning the employees of the Company or any of the Significant Subsidiaries and (iii) there has been
no violation of any federal, state, local or foreign law relating to discrimination in the hiring, promotion or pay of employees, any applicable wage or hour laws or any provision of the Employee Retirement Income Security Act of 1974
(“ERISA”) or the rules and regulations promulgated thereunder concerning the employees of the Company or any of the Significant Subsidiaries; 
 (bb) the Company and the Significant Subsidiaries and their respective properties, assets and operations are in compliance
with, and the Company and each of the Significant Subsidiaries hold all permits, authorizations and approvals required under, Environmental Laws (as defined below), except to the extent that failure to so comply or to hold such permits,
authorizations or approvals would not, individually or in the aggregate, have a Material Adverse Effect; there are no past, present or, to the Company’s knowledge, reasonably anticipated future events, conditions, circumstances, activities,
practices, actions, omissions or plans that could reasonably be expected to give rise to any material costs or liabilities to the Company or any Significant Subsidiary under, or to interfere with or prevent compliance by the Company or any
Significant Subsidiary with, Environmental Laws; except as would not, individually or in the aggregate, have a Material Adverse Effect, neither the Company nor any of the Significant Subsidiaries (i) is the subject of any investigation,
(ii) has received any notice or claim, (iii) is a party to or affected by any pending or, to the Company’s knowledge, threatened action, suit or proceeding, (iv) is bound by any judgment, decree or order or (v) has entered
into any agreement, in each case relating to any alleged violation of any Environmental Law or any actual or alleged release or threatened release or cleanup at

  

 13 








 
any location of any Hazardous Materials (as defined below) (as used herein, “Environmental Law” means any federal, state, local or foreign law, statute, ordinance, rule,
regulation, order, decree, judgment, injunction, permit, license, authorization or other binding requirement, or common law, relating to health, safety or the protection, cleanup or restoration of the environment or natural resources, including
those relating to the distribution, processing, generation, treatment, storage, disposal, transportation, other handling or release or threatened release of Hazardous Materials, and “Hazardous Materials” means any material
(including, without limitation, pollutants, contaminants, hazardous or toxic substances or wastes) that is regulated by or may give rise to liability under any Environmental Law); 
 (cc) all tax returns required to be filed by the Company or any of the Significant Subsidiaries have been timely filed, and
all taxes and other assessments of a similar nature (whether imposed directly or through withholding) including any interest, additions to tax or penalties applicable thereto due or claimed to be due from such entities have been timely paid, other
than those with respect to which the Company or such Significant Subsidiary has filed for or received extensions or those being contested in good faith and for which adequate reserves have been provided, except where the failure to make such
required filings and payments would not, individually or in the aggregate, have a Material Adverse Effect; 
 (dd) the Company and each of the Significant Subsidiaries maintain insurance covering their respective properties, operations, personnel and businesses as the Company reasonably deems adequate; such insurance insures against such losses and
risks to an extent which the Company reasonably deems adequate to protect the Company and the Significant Subsidiaries and their respective businesses; all such insurance is fully in force on the date hereof and will be fully in force at the time of
purchase and each additional time of purchase, if any; neither the Company nor any Significant Subsidiary has reason to believe that it will not be able to renew any such insurance as and when such insurance expires; 
 (ee) neither the Company nor any Significant Subsidiary has sent or received any communication regarding termination of, or
intent not to renew, any of the material contracts or agreements referred to or described, on an individual basis, in any Pre-Pricing Prospectus, the Prospectus or any Permitted Free Writing Prospectus, or referred to or described in, or filed as an
exhibit to, the Registration Statement or any Incorporated Document, and no such termination or non-renewal has been threatened by the Company or any Significant Subsidiary or, to the Company’s knowledge, any other party to any such contract or
agreement; 
 (ff) the Company and each of the Significant Subsidiaries maintain a system of internal accounting
controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with generally accepted accounting principles and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the
recorded accountability

  

 14 








 
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; 
 (gg) the Company has established and maintains and evaluates “disclosure controls and procedures” (as such term is
defined in Rule 13a-15 and 15d-15 under the Exchange Act) and “internal control over financial reporting” (as such term is defined in Rule 13a-15 and 15d-15 under the Exchange Act); such disclosure controls and procedures are designed to
ensure that material information relating to the Company, including its consolidated Subsidiaries, is made known to the Company’s Chief Executive Officer and its Chief Financial Officer by others within those entities, and such disclosure
controls and procedures are effective to perform the functions for which they were established; the Company’s independent auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant
deficiencies, if any, in the design or operation of internal controls which could adversely affect the Company’s ability to record, process, summarize and report financial data; and (ii) all fraud, if any, whether or not material, that
involves management or other employees who have a role in the Company’s internal controls; all material weaknesses, if any, in internal controls have been identified to the Company’s independent auditors; since the date of the most recent
evaluation of such disclosure controls and procedures and internal controls, there have been no significant changes in internal controls or in other factors that could significantly affect internal controls, including any corrective actions with
regard to significant deficiencies and material weaknesses; and the Company and its directors and officers are in material compliance with the applicable provisions of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) and
the rules and regulations promulgated thereunder, and have taken all necessary actions to ensure such compliance during the period during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule
172 under the Act or similar rule) in connection with any sale of Shares; 
 (hh) each “forward-looking
statement” (within the meaning of Section 27A of the Act or Section 21E of the Exchange Act) contained or incorporated by reference in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free
Writing Prospectuses, if any, has been made or reaffirmed with a reasonable basis and in good faith; 
 (ii) all
statistical or market-related data included or incorporated by reference in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, are based on or derived from sources that the
Company reasonably believes to be reliable and accurate, and the Company has obtained the written consent to the use of such data from such sources to the extent required; 
 (jj) neither the Company nor any of the Subsidiaries nor, to the Company’s knowledge, any employee or agent of the
Company or any Subsidiary has made any payment of funds of the Company or any Subsidiary or received or retained any funds in violation of any law, rule or regulation (including, without limitation, the Foreign Corrupt Practices Act of 1977), which
payment, receipt or retention of funds is of a character required to be disclosed in the Registration Statement, any Pre-Pricing Prospectus or the

  

 15 








 
Prospectus; 
 (kk) the operations of the Company and the
operations of the Subsidiaries since the time of formation or acquisition by the Company, are in material compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the
“Money Laundering Laws”); and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator or non-governmental authority involving the Company or any of the Subsidiaries with
respect to the Money Laundering Laws is pending or, to the Company’s knowledge, threatened; 
 (ll) neither
the Company nor any of the Subsidiaries nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company or any of the Subsidiaries is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will not directly or indirectly use the proceeds of the offering of the Shares contemplated hereby, or lend, contribute or otherwise make available
such proceeds to any Subsidiary, joint venture partner or other person or entity for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC; 
 (mm) no Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any
other distribution on such Subsidiary’s capital stock, from repaying to the Company any loans or advances to such Subsidiary from the Company or from transferring any of such Subsidiary’s property or assets to the Company or any other
Subsidiary of the Company, except as described in the Registration Statement (excluding the exhibits thereto), each Pre-Pricing Prospectus and the Prospectus; 
 (nn) the issuance and sale of the Shares as contemplated hereby will not cause any holder of any shares of capital stock,
securities convertible into or exchangeable or exercisable for capital stock or options, warrants or other rights to purchase capital stock or any other securities of the Company to have any right to acquire any shares of preferred stock of the
Company; 
 (oo) the Company has not received any notice from the NASDAQ regarding the delisting of the Common
Stock from the NASDAQ; 
 (pp) except pursuant to this Agreement, neither the Company nor any of the Subsidiaries
has incurred any liability for any finder’s or broker’s fee or agent’s commission in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby or by the Registration
Statement; 
 (qq) neither the Company nor any of the Subsidiaries nor any of their respective directors,
officers, affiliates or controlling persons has taken, directly or indirectly, any action designed, or which has constituted or might reasonably be expected

  

 16 








 
to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares; and 
 (rr) to the Company’s knowledge, there are no affiliations or associations between (i) any member of FINRA and
(ii) the Company or any of the Company’s officers, directors or 5% or greater security holders or any beneficial owner of the Company’s unregistered equity securities that were acquired at any time on or after the 180th day
immediately preceding the date the Registration Statement was initially filed with the Commission, except as disclosed in the Registration Statement (excluding the exhibits thereto), the Pre-Pricing Prospectuses and the Prospectus. 
 In addition, any certificate signed by any officer of the Company or any of the Subsidiaries and delivered to the Underwriters or counsel
for the Underwriters in connection with the offering of the Shares shall be deemed to be a representation and warranty by the Company, as to matters covered thereby, to each Underwriter. 
 4. Certain Covenants of the Company. The Company hereby agrees: 
 (a) to furnish such information as may be required and otherwise to cooperate in qualifying the Shares for offering and sale
under the securities or blue sky laws of such states or other jurisdictions as the Representatives may designate and to maintain such qualifications in effect so long as the Representatives may request for the distribution of the Shares;
provided, however, that the Company shall not be required to qualify as a foreign corporation or to consent to the service of process under the laws of any such jurisdiction (except service of process with respect to the offering and
sale of the Shares); and to promptly advise the Representatives of the receipt by the Company of any notification with respect to the suspension of the qualification of the Shares for offer or sale in any jurisdiction or the initiation or
threatening of any proceeding for such purpose; 
 (b) to make available to the Underwriters in New York City, as
soon as practicable after this Agreement becomes effective, and thereafter from time to time to furnish to the Underwriters, as many copies of the Prospectus (or of the Prospectus as amended or supplemented if the Company shall have made any
amendments or supplements thereto after the effective date of the Registration Statement) as the Underwriters may reasonably request for the purposes contemplated by the Act; in case any Underwriter is required to deliver (whether physically or
through compliance with Rule 172 under the Act or any similar rule), in connection with the sale of the Shares, a prospectus after the nine-month period referred to in Section 10(a)(3) of the Act or after the time a post-effective amendment to
the Registration Statement is required pursuant to Item 512(a) of Regulation S-K under the Act, the Company will prepare, at its expense, promptly upon request such amendment or amendments to the Registration Statement and the Prospectus as may
be necessary to permit compliance with the requirements of Section 10(a)(3) of the Act or Item 512(a) of Regulation S-K under the Act, as the case may be; 
 (c) if, at the time this Agreement is executed and delivered, it is necessary or appropriate for a post-effective amendment
to the Registration Statement, or a

  

 17 








 
Registration Statement under Rule 462(b) under the Act, to be filed with the Commission and become effective before the Shares may be sold, the Company will use its reasonable commercial efforts
to cause such post-effective amendment or such Registration Statement to be filed and become effective, and will pay any applicable fees in accordance with the Act, as soon as possible; and the Company will advise the Representatives promptly and,
if requested by the Representatives, will confirm such advice in writing, (i) when such post-effective amendment or such Registration Statement has become effective, and (ii) if Rule 430A under the Act is used, when the Prospectus is filed
with the Commission pursuant to Rule 424(b) under the Act (which the Company agrees to file in a timely manner in accordance with such Rules); 
 (d) if, at any time during the period when a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule) in connection with
any sale of Shares, the Registration Statement shall cease to comply with the requirements of the Act with respect to eligibility for the use of the form on which the Registration Statement was filed with the Commission, to (i) promptly notify
the Representatives, (ii) promptly file with the Commission a new registration statement under the Act, relating to the Shares, or a post-effective amendment to the Registration Statement, which new registration statement or post-effective
amendment shall comply with the requirements of the Act and shall be in a form satisfactory to the Representatives, (iii) use its reasonable commercial efforts to cause such new registration statement or post-effective amendment to become
effective under the Act as soon as practicable, (iv) promptly notify the Representatives of such effectiveness and (v) take all other action necessary and appropriate to permit the public offering and sale of the Shares to continue as
contemplated in the Prospectus; all references herein to the Registration Statement shall be deemed to include each such new registration statement or post-effective amendment, if any; 
 (e) if the third anniversary of the initial effective date of the Registration Statement (within the meaning of Rule
415(a)(5) under the Act) shall occur at any time during the period when a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule) in connection with any sale of
Shares, to (i) file with the Commission, prior to such third anniversary, a new registration statement under the Act relating to the Shares, which new registration statement shall comply with the requirements of the Act (including, without
limitation, Rule 415(a)(6) under the Act) and shall be in a form reasonably satisfactory to the Representatives; and (ii) use its best efforts to cause such new registration statement to become effective under the Act as soon as practicable,
but in any event within 180 days after such third anniversary and promptly notify the Representatives of such effectiveness; the Company shall take all other action necessary and appropriate to permit the public offering and sale of the Shares to
continue as contemplated in the Prospectus; all references herein to the Registration Statement shall be deemed to include each such new registration statement, if any; 
 (f) to advise the Representatives promptly, confirming such advice in writing, of any request by the Commission for
amendments or supplements to the Registration Statement, any Pre-Pricing Prospectus, the Prospectus or any Permitted Free Writing

  

 18 








 
Prospectus or for additional information with respect thereto, or of notice of institution of proceedings for, or the entry of a stop order, suspending the effectiveness of the Registration
Statement and, if the Commission should enter a stop order suspending the effectiveness of the Registration Statement, to use its reasonable commercial efforts to obtain the lifting or removal of such order as soon as possible; to advise the
Representatives promptly of any proposal to amend or supplement the Registration Statement, any Pre-Pricing Prospectus or the Prospectus, and to provide the Representatives and Underwriters’ counsel copies of any such documents for review and
comment a reasonable amount of time prior to any proposed filing and to file no such amendment or supplement to which the Representatives shall object in writing; 
 (g) to file promptly all reports and documents and any preliminary or definitive proxy or information statement required to
be filed by the Company with the Commission in order to comply with the Exchange Act for so long as a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule) in
connection with any sale of Shares; and to promptly provide you with a copy of such reports and statements and other documents filed by the Company pursuant to Section 13, 14 or 15(d) of the Exchange Act through the expiration of the
Over-Allotment Option; 
 (h) to advise the Underwriters promptly of the happening of any event within the period
during which a prospectus is required by the Act to be delivered (whether physically or through compliance with Rule 172 under the Act or any similar rule) in connection with any sale of Shares, which event could require the making of any change in
the Prospectus then being used so that the Prospectus would not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they are
made, not misleading, and to advise the Underwriters promptly if, during such period, it shall become necessary to amend or supplement the Prospectus to cause the Prospectus to comply with the requirements of the Act, and, in each case, during such
time, to prepare and furnish, at the Company’s expense, to the Underwriters promptly such amendments or supplements to such Prospectus as may be necessary to reflect any such change or to effect such compliance; 
 (i) to make generally available to its security holders, and to deliver to the Representatives, an earnings statement of the
Company (which will satisfy the provisions of Section 11(a) of the Act) covering a period of twelve months beginning after the effective date of the Registration Statement (as defined in Rule 158(c) under the Act) as soon as is reasonably
practicable after the termination of such twelve-month period but in any case not later than the first date by which the Company is required to file with the Commission a Quarterly Report on Form 10-Q or Annual Report on Form 10-K that is required
to include financial statements covering a period that includes the last month of such twelve-month period; 
 (j) to furnish to the Representatives three copies of the Registration Statement, as initially filed with the Commission, and of all amendments thereto (including all exhibits thereto and documents incorporated by reference therein) and

  

 19 








 
sufficient copies of the foregoing (other than exhibits) for distribution of a copy to each of the other Underwriters; 
 (k) to furnish to the Representatives as early as practicable prior to the time of purchase and any additional time of
purchase, as the case may be, but not later than two business days prior thereto, a copy of the latest available unaudited interim and monthly consolidated financial statements, if any, of the Company and the Subsidiaries which have been read by the
Company’s independent registered public accountants, as stated in their letter to be furnished pursuant to Section 6(f) hereof; 
 (l) to apply the net proceeds from the sale of the Shares in the manner set forth under the caption “Use of Proceeds” in the Prospectus Supplement; 
 (m) to pay all costs, expenses, fees and taxes in connection with (i) the preparation and filing of the Registration
Statement, each Basic Prospectus, each Pre-Pricing Prospectus, the Prospectus Supplement, the Prospectus, each Permitted Free Writing Prospectus and any amendments or supplements thereto, and the printing and furnishing of copies of each thereof to
the Underwriters and to dealers (including costs of mailing and shipment), (ii) the registration, issue, sale and delivery of the Shares including any stock or transfer taxes and stamp or similar duties payable upon the sale, issuance or
delivery of the Shares to the Underwriters, (iii) the producing, word processing and/or printing of this Agreement, any Agreement Among Underwriters, any dealer agreements, any Powers of Attorney and any closing documents (including
compilations thereof) and the reproduction and/or printing and furnishing of copies of each thereof to the Underwriters and (except closing documents) to dealers (including costs of mailing and shipment), (iv) the qualification of the Shares
for offering and sale under state or foreign laws and the determination of their eligibility for investment under state or foreign law and the printing and furnishing of copies of any blue sky surveys or legal investment surveys to the Underwriters
and to dealers, and the legal fees in connection therewith, (v) any listing of the Shares on any securities exchange or qualification of the Shares for quotation on the NASDAQ and any registration thereof under the Exchange Act, (vi) any
filing for review of the public offering of the Shares by FINRA, and the legal fees in connection therewith, (vii) the fees and disbursements of any transfer agent or registrar for the Shares, (viii) the costs and expenses of the Company
relating to presentations or meetings undertaken in connection with the marketing of the offering and sale of the Shares to prospective investors and the Underwriters’ sales forces, including, without limitation, expenses associated with the
production of road show slides and graphics, reasonable costs and fees for travel, lodging and other expenses incurred by the officers of the Company and the Underwriters, and the cost of any aircraft chartered in connection with the road show
(provided that no aircraft shall be chartered without the prior consent of the Company, which consent may be the oral consent of the Chief Executive Officer or the Chief Financial Officer), and (ix) the performance of the Company’s other
obligations hereunder. Except as provided in this Section 4(m) and Sections 5 and 9 hereof, the Underwriters shall pay their own expenses, including the fees and disbursements of their counsel; 
 (n) to comply with Rule 433(d) under the Act (without reliance on Rule

  

 20 








 
164(b) under the Act) and with Rule 433(g) under the Act; 
 (o) beginning on the date hereof and ending on, and including, the date that is 90 days after the date of the Prospectus Supplement (the “Lock-Up Period”), without the prior written consent of William Blair, not to
(i) issue, sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate
or decrease a call equivalent position within the meaning of Section 16 of the Exchange Act and the rules and regulations of the Commission promulgated thereunder, with respect to, any Common Stock or any other securities of the Company that
are substantially similar to Common Stock, or any securities convertible into or exchangeable or exercisable for, or any warrants or other rights to purchase, the foregoing, (ii) file or cause to become effective a registration statement under
the Act relating to the offer and sale of any Common Stock or any other securities of the Company that are substantially similar to Common Stock, or any securities convertible into or exchangeable or exercisable for, or any warrants or other rights
to purchase, the foregoing, (iii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of Common Stock or any other securities of the Company that are
substantially similar to Common Stock, or any securities convertible into or exchangeable or exercisable for, or any warrants or other rights to purchase, the foregoing, whether any such transaction is to be settled by delivery of Common Stock or
such other securities, in cash or otherwise or (iv) publicly announce an intention to effect any transaction specified in clause (i), (ii) or (iii), except, in each case, for (A) the registration of the offer and sale of the Shares as
contemplated by this Agreement, (B) issuances of Common Stock upon the exercise of options or warrants disclosed as outstanding in the Registration Statement (excluding the exhibits thereto), each Pre-Pricing Prospectus and the Prospectus,
(C) the issuance to employees, directors or officers of restricted stock grants, restricted stock units, stock options or other awards as allowable under the Company’s 2006 Long-Term Equity Incentive Plan in connection with
(i) quarterly director compensation distributions, (ii) ordinary course compensation practices, or (iii) newly hired employees, (D) the issuance of Common Stock to employees under the Company’s employee stock purchase plan,
and (E) the issuance of restricted stock units or other equity instruments in connection with acquisition activities, provided that such restricted stock units do not vest during this Lock-Up Period; provided, however, that if
(a) during the period that begins on the date that is fifteen (15) calendar days plus three (3) business days before the last day of the Lock-Up Period and ends on the last day of the Lock-Up Period, the Company issues an earnings
release or material news or a material event relating to the Company occurs; or (b) prior to the expiration of the Lock-Up Period, the Company announces that it will release earnings results during the sixteen (16) day period beginning on
the last day of the Lock-Up Period, then the restrictions imposed by this Section 4(o) shall continue to apply until the expiration of the date that is fifteen (15) calendar days plus three (3) business days after the date on which
the issuance of the earnings release or the material news or material event occurs (the “Extended Period”), except that the restrictions imposed by this Section 4(o) shall not continue to apply during the Extended Period so
long as the Company meets the registrant requirements set forth in Rule 139 under the Act for the publishing of issuer-specific research reports; 
  

 21 








 (p) prior to the time of purchase or any additional time of purchase, as the
case may be, to issue no press release or other communication directly or indirectly and hold no press conferences with respect to the Company or any Subsidiary, the financial condition, results of operations, business, properties, assets, or
liabilities of the Company or any Subsidiary, or the offering of the Shares, without the Representatives’ prior consent, which shall not be unreasonably withheld; 
 (q) not, at any time at or after the execution of this Agreement, to, directly or indirectly, offer or sell any Shares by
means of any “prospectus” (within the meaning of the Act), or use any “prospectus” (within the meaning of the Act) in connection with the offer or sale of the Shares, in each case other than the Prospectus; 
 (r) not to, and to cause the Subsidiaries not to, take, directly or indirectly, any action designed, or which will
constitute, or has constituted, or might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares; 
 (s) to use its best efforts to cause the Shares to be listed for quotation on the NASDAQ and to maintain the listing of the
Common Stock, including the Shares, for quotation on the NASDAQ; and 
 (t) to maintain a transfer agent and, if
necessary under the jurisdiction of incorporation of the Company, a registrar for the Common Stock. 
 5. Reimbursement of
Underwriters’ Expenses. If the Shares are not delivered for any reason other than the termination of this Agreement pursuant to the fifth paragraph of Section 8 hereof or the default by one or more of the Underwriters in its or their
respective obligations hereunder, the Company shall, in addition to paying the amounts described in Section 4(m) hereof, reimburse the Underwriters for all of their reasonable out-of-pocket expenses, including the fees and disbursements of
their counsel. 
 6. Conditions of Underwriters’ Obligations. The several obligations of the Underwriters hereunder
are subject to the accuracy of the representations and warranties on the part of the Company on the date hereof, at the time of purchase and, if applicable, at the additional time of purchase, the performance by the Company of its obligations
hereunder and to the following additional conditions precedent: 
 (a) The Company shall furnish to the
Representatives at the time of purchase and, if applicable, at the additional time of purchase, an opinion of Squire, Sanders & Dempsey L.L.P., counsel for the Company, addressed to the Underwriters, and dated the time of purchase or the
additional time of purchase, as the case may be, with executed copies for each of the other Underwriters, and in form and substance satisfactory to William Blair, in the form set forth in Exhibit B hereto. 
 (b) The Representatives shall have received (i) from Grant Thornton LLP letters dated, respectively, the date of this
Agreement, the date of the Prospectus Supplement, the time of purchase and, if applicable, the additional time of purchase, and addressed to the Underwriters (with executed copies for each of the Underwriters) in the

  

 22 








 
forms satisfactory to William Blair, which letters shall cover, without limitation, the various financial disclosures contained in the Registration Statement, the Pre-Pricing Prospectus, the
Prospectus and the Permitted Free Writing Prospectuses, if any; and (ii) from KPMG LLP letters dated, respectively, the date of this Agreement, the date of the Prospectus Supplement, the time of purchase and, if applicable, the additional time
of purchase, and addressed to the Underwriters (with executed copies for each of the Underwriters) in the forms satisfactory to William Blair, which letters shall cover, without limitation, the various financial disclosures relating to Macro
contained in the Registration Statement, the Pre-Pricing Prospectus, the Prospectus and the Permitted Free Writing Prospectuses, if any. 
 (c) The Representatives shall have received at the time of purchase and, if applicable, at the additional time of purchase, the favorable opinion of Davis Polk & Wardwell LLP, counsel for the
Underwriters, dated the time of purchase or the additional time of purchase, as the case may be, in form and substance reasonably satisfactory to William Blair. 
 (d) No Prospectus or amendment or supplement to the Registration Statement or the Prospectus shall have been filed to which
the Representatives shall have objected in writing. 
 (e) The Registration Statement and any registration
statement required to be filed, prior to the sale of the Shares, under the Act pursuant to Rule 462(b) shall have been filed and shall have become effective under the Act. The Prospectus Supplement shall have been filed with the Commission pursuant
to Rule 424(b) under the Act at or before 5:30 P.M., New York City time, on the second full business day after the date of this Agreement (or such earlier time as may be required under the Act). 
 (f) Prior to and at the time of purchase, and, if applicable, the additional time of purchase, (i) no stop order with
respect to the effectiveness of the Registration Statement shall have been issued under the Act or proceedings initiated under Section 8(d) or 8(e) of the Act; (ii) the Registration Statement and all amendments thereto shall not contain an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (iii) none of the Pre-Pricing Prospectus or the Prospectus, and no amendment or
supplement thereto, shall include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they are made, not misleading; (iv) no
Disclosure Package, and no amendment or supplement thereto, shall include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they
are made, not misleading; and (v) none of the Permitted Free Writing Prospectuses, if any, shall include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they are made, not misleading. 
 (g) The Company will, at the time of purchase
and, if applicable, at the additional time of purchase, deliver to the Representatives a certificate of its Chief

  

 23 








 
Executive Officer and its Chief Financial Officer, dated the time of purchase or the additional time of purchase, as the case may be, in the form attached as Exhibit C hereto. 

(h) The Representatives shall have received each of the signed Lock-Up Agreements referred to in Section 3(w) hereof,
and each such Lock-Up Agreement shall be in full force and effect at the time of purchase and the additional time of purchase, as the case may be. 
 (i) The Company shall have furnished to the Representatives such other documents and certificates as to the accuracy and completeness of any statement in the Registration Statement, any Pre-Pricing
Prospectus, the Prospectus or any Permitted Free Writing Prospectus as of the time of purchase and, if applicable, the additional time of purchase, as the Representatives may reasonably request. 
 (j) The Shares shall have been approved for listing on and for quotation on the NASDAQ, subject only to notice of issuance at
or prior to the time of purchase or the additional time of purchase, as the case may be. 
 (k) FINRA shall not
have raised any objection with respect to the fairness or reasonableness of the underwriting, or other arrangements of the transactions, contemplated hereby. 
 7. Effective Date of Agreement; Termination. This Agreement shall become effective when the parties hereto have executed and delivered this Agreement. 
 The obligations of the several Underwriters hereunder shall be subject to termination in the absolute discretion of William Blair, if
(1) since the time of execution of this Agreement or the earlier respective dates as of which information is given in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if
any, there has been any change or any development involving a prospective change in the business, properties, management, financial condition or results of operations of the Company and the Subsidiaries taken as a whole, that was not, at the
time of execution of this Agreement, otherwise reflected in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, the effect of which change or development is, in the sole
judgment of William Blair, so material and adverse as to make it impractical or inadvisable to proceed with the public offering or the delivery of the Shares on the terms and in the manner contemplated in the Registration Statement, the Pre-Pricing
Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, or (2) since the time of execution of this Agreement, there shall have occurred: (A) a suspension or material limitation in trading in securities generally
on the NYSE, the American Stock Exchange or the NASDAQ; (B) a suspension or material limitation in trading in the Company’s securities on the NASDAQ; (C) a general moratorium on commercial banking activities declared by either federal
or New York State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States; (D) an outbreak or escalation of hostilities or acts of terrorism involving the United States or a
declaration by the United States of a national emergency or war; or (E) any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of any such event specified

  

 24 








 
in clause (D) or (E), in the sole judgment of William Blair, makes it impractical or inadvisable to proceed with the public offering or the delivery of the Shares on the terms and in the
manner contemplated in the Registration Statement, the Pre-Pricing Prospectuses, the Prospectus and the Permitted Free Writing Prospectuses, if any, or (3) since the time of execution of this Agreement, there shall have occurred any
downgrading, or any notice or announcement shall have been given or made of: (A) any intended or potential downgrading or (B) any watch, review or possible change that does not indicate an affirmation or improvement in the rating accorded
any securities of or guaranteed by the Company or any Subsidiary by any “nationally recognized statistical rating organization,” as that term is defined in Rule 436(g)(2) under the Act. 
 If William Blair elects to terminate this Agreement as provided in this Section 7, the Company and each other Underwriter shall be
notified promptly in writing. 
 If the sale to the Underwriters of the Shares, as contemplated by this Agreement, is not
carried out by the Underwriters for any reason permitted under this Agreement, or if such sale is not carried out because the Company shall be unable to comply with any of the terms of this Agreement, the Company shall not be under any obligation or
liability under this Agreement (except to the extent provided in Sections 4(m), 5 and 9 hereof), and the Underwriters shall be under no obligation or liability to the Company under this Agreement (except to the extent provided in Section 9
hereof) or to one another hereunder. 
 8. Increase in Underwriters’ Commitments. Subject to Sections 6 and 7
hereof, if any Underwriter shall default in its obligation to take up and pay for the Firm Shares to be purchased by it hereunder (otherwise than for a failure of a condition set forth in Section 6 hereof or a reason sufficient to justify the
termination of this Agreement under the provisions of Section 7 hereof) and if the number of Firm Shares which all Underwriters so defaulting shall have agreed but failed to take up and pay for does not exceed 10% of the total number of Firm
Shares, the non-defaulting Underwriters (including the Underwriters, if any, substituted in the manner set forth below) shall take up and pay for (in addition to the aggregate number of Firm Shares they are obligated to purchase pursuant to
Section 1 hereof) the number of Firm Shares agreed to be purchased by all such defaulting Underwriters, as hereinafter provided. Such Shares shall be taken up and paid for by such non-defaulting Underwriters in such amount or amounts as the
Representatives may designate with the consent of each Underwriter so designated or, in the event no such designation is made, such Shares shall be taken up and paid for by all non-defaulting Underwriters pro rata in proportion to the aggregate
number of Firm Shares set forth opposite the names of such non-defaulting Underwriters in Schedule A annexed hereto. 
 Without relieving any defaulting Underwriter from its obligations hereunder, the Company agrees with the non-defaulting Underwriters that it will not sell any Firm Shares to the Underwriters under this Agreement unless all of the Firm
Shares are purchased by the Underwriters (or by substituted Underwriters selected by the Representatives with the approval of the Company or selected by the Company with the Representatives’ approval). 
 If a new Underwriter or Underwriters are substituted by the Underwriters or by the Company for a defaulting Underwriter or Underwriters in
accordance with the foregoing provision, the Company or the Representatives shall have the right to postpone the time of purchase for a period not exceeding five business days in order that any necessary changes in the

  

 25 








 
Registration Statement and the Prospectus and other documents may be effected. 
 The term “Underwriter” as used in this Agreement shall refer to and include any Underwriter substituted under this Section 8 with like effect as if such substituted Underwriter had originally been named in Schedule A
annexed hereto. 
 If the aggregate number of Firm Shares which the defaulting Underwriter or Underwriters agreed to purchase
exceeds 10% of the total number of Firm Shares which all Underwriters agreed to purchase hereunder, and if neither the non-defaulting Underwriters nor the Company shall make arrangements within the five business day period stated above for the
purchase of all the Firm Shares which the defaulting Underwriter or Underwriters agreed to purchase hereunder, this Agreement shall terminate without further act or deed and without any liability on the part of the Company to any Underwriter and
without any liability on the part of any non-defaulting Underwriter to the Company. Nothing in this paragraph, and no action taken hereunder, shall relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under
this Agreement. 
 9. Indemnity and Contribution. 
 (a) The Company agrees to indemnify, defend and hold harmless each Underwriter, its partners, directors, officers, and
employees and any person who controls any Underwriter within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and the successors and assigns of all of the foregoing persons, from and against any loss, damage,
expense, liability or claim (including the reasonable cost of investigation) which, jointly or severally, any such Underwriter or any such person may incur under the Act, the Exchange Act, the common law or otherwise, insofar as such loss, damage,
expense, liability or claim arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or in the Registration Statement as amended by any post-effective
amendment thereof by the Company) or arises out of or is based upon any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as any such loss,
damage, expense, liability or claim arises out of or is based upon any untrue statement or alleged untrue statement of a material fact contained in, and in conformity with information concerning such Underwriter furnished in writing by or on behalf
of such Underwriter through the Representatives to the Company expressly for use in, the Registration Statement or arises out of or is based upon any omission or alleged omission to state a material fact in the Registration Statement in connection
with such information, which material fact was not contained in such information and which material fact was required to be stated in such Registration Statement or was necessary to make such information not misleading or (ii) any untrue
statement or alleged untrue statement of a material fact included in any Prospectus (the term Prospectus for the purpose of this Section 9 being deemed to include any Basic Prospectus, any Pre-Pricing Prospectus, the Prospectus Supplement, the
Prospectus and any amendments or supplements to the foregoing), in any Permitted Free Writing Prospectus, in any “issuer information” (as defined in Rule 433 under the Act) of the Company, which “issuer information” is required
to be, or is, filed with the Commission, or in any Prospectus together with any combination of one or more of the

  

 26 








 
Permitted Free Writing Prospectuses, if any, or arises out of or is based upon any omission or alleged omission to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading, except, with respect to such Prospectus or Permitted Free Writing Prospectus, insofar as any such loss, damage, expense, liability or claim arises out of or is based upon any
untrue statement or alleged untrue statement of a material fact contained in, and in conformity with information concerning such Underwriter furnished in writing by or on behalf of such Underwriter through the Representatives to the Company
expressly for use in, such Prospectus or Permitted Free Writing Prospectus or arises out of or is based upon any omission or alleged omission to state a material fact in such Prospectus or Permitted Free Writing Prospectus in connection with such
information, which material fact was not contained in such information and which material fact was necessary in order to make the statements in such information, in the light of the circumstances under which they were made, not misleading.

 (b) Each Underwriter severally agrees to indemnify, defend and hold harmless the Company, its directors and
officers, and any person who controls the Company within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and the successors and assigns of all of the foregoing persons, from and against any loss, damage, expense,
liability or claim (including the reasonable cost of investigation) which, jointly or severally, the Company or any such person may incur under the Act, the Exchange Act, the common law or otherwise, insofar as such loss, damage, expense, liability
or claim arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in, and in conformity with information concerning such Underwriter furnished in writing by or on behalf of such
Underwriter through the Representatives to the Company expressly for use in, the Registration Statement (or in the Registration Statement as amended by any post-effective amendment thereof by the Company), or arises out of or is based upon any
omission or alleged omission to state a material fact in such Registration Statement in connection with such information, which material fact was not contained in such information and which material fact was required to be stated in such
Registration Statement or was necessary to make such information not misleading or (ii) any untrue statement or alleged untrue statement of a material fact contained in, and in conformity with information concerning such Underwriter furnished
in writing by or on behalf of such Underwriter through the Representatives to the Company expressly for use in, a Prospectus or a Permitted Free Writing Prospectus, or arises out of or is based upon any omission or alleged omission to state a
material fact in such Prospectus or Permitted Free Writing Prospectus in connection with such information, which material fact was not contained in such information and which material fact was necessary in order to make the statements in such
information, in the light of the circumstances under which they were made, not misleading. 
 (c) If any action,
suit or proceeding (each, a “Proceeding”) is brought against a person (an “indemnified party”) in respect of which indemnity may be sought against the Company or an Underwriter (as applicable, the
“indemnifying party”) pursuant to subsection (a) or (b), respectively, of this Section 9, such indemnified party shall promptly notify such indemnifying party in writing of the institution of such Proceeding and such
indemnifying party shall assume the defense of such Proceeding, including the

  

 27 








 
employment of counsel reasonably satisfactory to such indemnified party and payment of all fees and expenses; provided, however, that the omission to so notify such indemnifying
party shall not relieve such indemnifying party from any liability which such indemnifying party may have to any indemnified party or otherwise. The indemnified party or parties shall have the right to employ its or their own counsel in any such
case, but the fees and expenses of such counsel shall be at the expense of such indemnified party or parties unless the employment of such counsel shall have been authorized in writing by the indemnifying party in connection with the defense of such
Proceeding or the indemnifying party shall not have, within a reasonable period of time in light of the circumstances, employed counsel to defend such Proceeding or such indemnified party or parties shall have reasonably concluded that there may be
defenses available to it or them which are different from, additional to or in conflict with those available to such indemnifying party (in which case such indemnifying party shall not have the right to direct the defense of such Proceeding on
behalf of the indemnified party or parties), in any of which events such fees and expenses shall be borne by such indemnifying party and paid as incurred (it being understood, however, that such indemnifying party shall not be liable for the
expenses of more than one separate counsel (in addition to any local counsel) in any one Proceeding or series of related Proceedings in the same jurisdiction representing the indemnified parties who are parties to such Proceeding). The indemnifying
party shall not be liable for any settlement of any Proceeding effected without its written consent but, if settled with its written consent, such indemnifying party agrees to indemnify and hold harmless the indemnified party or parties from and
against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as
contemplated by the second sentence of this Section 9(c), then the indemnifying party agrees that it shall be liable for any settlement of any Proceeding effected without its written consent if (i) such settlement is entered into more than
60 business days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall not have fully reimbursed the indemnified party in accordance with such request prior to the date of such settlement and
(iii) such indemnified party shall have given the indemnifying party at least 30 days’ prior notice of its intention to settle. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement
of any pending or threatened Proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of
such indemnified party from all liability on claims that are the subject matter of such Proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party. 
 (d) If the indemnification provided for in this Section 9 is unavailable to an indemnified party under subsections
(a) and (b) of this Section 9 or insufficient to hold an indemnified party harmless in respect of any losses, damages, expenses, liabilities or claims referred to therein, then each applicable indemnifying party shall contribute to
the amount paid or payable by such indemnified party as a result of such losses, damages, expenses, liabilities or claims (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the
Underwriters on the other

  

 28 








 
hand from the offering of the Shares or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only
the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one hand and of the Underwriters on the other in connection with the statements or omissions which resulted in such losses, damages,
expenses, liabilities or claims, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same respective proportions as the
total proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by the Company, and the total underwriting discounts and commissions received by the Underwriters, bear to the aggregate public
offering price of the Shares. The relative fault of the Company on the one hand and of the Underwriters on the other shall be determined by reference to, among other things, whether the untrue statement or alleged untrue statement of a material fact
or omission or alleged omission relates to information supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The
amount paid or payable by a party as a result of the losses, damages, expenses, liabilities and claims referred to in this subsection shall be deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with
investigating, preparing to defend or defending any Proceeding. 
 (e) The Company and the Underwriters agree
that it would not be just and equitable if contribution pursuant to this Section 9 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not
take account of the equitable considerations referred to in subsection (d) above. Notwithstanding the provisions of this Section 9, no Underwriter shall be required to contribute any amount in excess of the amount by which the total price
at which the Shares underwritten by such Underwriter and distributed to the public were offered to the public exceeds the amount of any damage which such Underwriter has otherwise been required to pay by reason of such untrue statement or alleged
untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. The Underwriters’ obligations to contribute pursuant to this Section 9 are several in proportion to their respective underwriting commitments and not joint. 
 (f) The indemnity and contribution agreements contained in this Section 9 and the covenants, warranties and
representations of the Company contained in this Agreement shall remain in full force and effect regardless of any investigation made by or on behalf of any Underwriter, its partners, directors or officers or any person (including each partner,
officer or director of such person) who controls any Underwriter within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, or by or on behalf of the Company, its directors or officers or any person who controls the
Company within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and shall survive any termination of this Agreement or the issuance and delivery of the Shares. The Company and each Underwriter agree promptly to
notify each other of the commencement of any Proceeding against it and, in the case of the Company, against any

  

 29 








 
of the Company’s officers or directors in connection with the issuance and sale of the Shares, or in connection with the Registration Statement, any Basic Prospectus, any Pre-Pricing
Prospectus, the Prospectus or any Permitted Free Writing Prospectus. 
 10. Information Furnished by the Underwriters.
The statements set forth in the third-to-last paragraph on the cover page of the Prospectus; the first paragraph immediately under the subheading “Underwriting—Over-Allotment Option,” the first paragraph immediately under the
subheading “Underwriting—Commissions and Discounts” and the paragraphs under the subheading “Underwriting—Price-Stabilization, Short Positions, Passive Market-Making,” constitute the only information furnished by or on
behalf of the Underwriters, as such information is referred to in Sections 3 and 9 hereof. 
 11. Notices. Except as
otherwise herein provided, all statements, requests, notices and agreements shall be in writing or by telegram or facsimile and, if to the Underwriters, shall be sufficient in all respects if delivered or sent to William Blair & Company,
L.L.C. at 222 West Adams Street, Chicago, Illinois 60606, Attention: Equity Syndicate Department, (facsimile: 312-236-8991)
 e-mail: eqsyndicate@williamblair.com and, if to the Company, shall be sufficient in all respects if delivered or
sent to the Company at the offices of the Company at 9300 Lee Highway, Fairfax, Virginia 22031, Attention: Sudhakar Kesavan, Chairman & Chief Executive Officer (facsimile: 703-934-3740) e-mail: SKesavan@icfi.com. 
 12. Governing Law; Construction. This Agreement and any claim, counterclaim or dispute of any kind or nature whatsoever arising out
of or in any way relating to this Agreement (“Claim”), directly or indirectly, shall be governed by, and construed in accordance with, the laws of the State of New York. The section headings in this Agreement have been inserted as a
matter of convenience of reference and are not a part of this Agreement. 
 13. Submission to Jurisdiction. Except as set
forth below, no Claim may be commenced, prosecuted or continued in any court other than the courts of the State of New York located in the City and County of New York or in the United States District Court for the Southern District of New York,
which courts shall have jurisdiction over the adjudication of such matters, and the Company consents to the jurisdiction of such courts and personal service with respect thereto. The Company hereby consents to personal jurisdiction, service and
venue in any court in which any Claim arising out of or in any way relating to this Agreement is brought by any third party against any Underwriter or any indemnified party. Each Underwriter and the Company (on its behalf and, to the extent
permitted by applicable law, on behalf of its stockholders and affiliates) waive all right to trial by jury in any action, proceeding or counterclaim (whether based upon contract, tort or otherwise) in any way arising out of or relating to this
Agreement. The Company agrees that a final judgment in any such action, proceeding or counterclaim brought in any such court shall be conclusive and binding upon the Company and may be enforced in any other courts to the jurisdiction of which the
Company is or may be subject, by suit upon such judgment. 
 14. Parties at Interest. The Agreement herein set forth has
been and is made solely for the benefit of the Underwriters and the Company and to the extent provided in Section 9 hereof the controlling persons, partners, directors and officers referred to in such Section, and their respective successors,
assigns, heirs, personal representatives and executors and

  

 30 








 
administrators. No other person, partnership, association or corporation (including a purchaser, as such purchaser, from any of the Underwriters) shall acquire or have any right under or by
virtue of this Agreement. 
 15. No Fiduciary Relationship. The Company hereby acknowledges that the Underwriters are
acting solely as underwriters in connection with the purchase and sale of the Company’s securities. The Company further acknowledges that the Underwriters are acting pursuant to a contractual relationship created solely by this Agreement
entered into on an arm’s length basis, and in no event do the parties intend that the Underwriters act or be responsible as a fiduciary to the Company, its management, stockholders or creditors or any other person in connection with any
activity that the Underwriters may undertake or have undertaken in furtherance of the purchase and sale of the Company’s securities, either before or after the date hereof. The Underwriters hereby expressly disclaim any fiduciary or similar
obligations to the Company, either in connection with the transactions contemplated by this Agreement or any matters leading up to such transactions, and the Company hereby confirms its understanding and agreement to that effect. The Company and the
Underwriters agree that they are each responsible for making their own independent judgments with respect to any such transactions and that any opinions or views expressed by the Underwriters to the Company regarding such transactions, including,
but not limited to, any opinions or views with respect to the price or market for the Company’s securities, do not constitute advice or recommendations to the Company. The Company hereby waives and releases, to the fullest extent permitted by
law, any claims that the Company may have against the Underwriters with respect to any breach or alleged breach of any fiduciary or similar duty to the Company in connection with the transactions contemplated by this Agreement or any matters leading
up to such transactions. 
 16. Counterparts. This Agreement may be signed by the parties in one or more counterparts
which together shall constitute one and the same agreement among the parties. 
 17. Successors and Assigns. This
Agreement shall be binding upon the Underwriters and the Company and their successors and assigns and any successor or assign of any substantial portion of the Company’s and any of the Underwriters’ respective businesses and/or assets.

 [The Remainder of This Page Intentionally Left Blank; Signature Pages Follow] 
  

 31 








 If the foregoing correctly sets forth the understanding among the Company and the several
Underwriters, please so indicate in the space provided below for that purpose, whereupon this Agreement and the Representatives’ acceptance shall constitute a binding agreement among the Company and the Underwriters, severally. 
  

			
	Very truly yours,
	
	ICF INTERNATIONAL, INC.
		
	By: 	 	/s/ Sudhakar Kesavan
		 	Name: Sudhakar Kesavan
		 	Title:   Chairman and CEO











 Accepted and agreed to as of the date first above written, on behalf of themselves and the other several
Underwriters named in Schedule A annexed hereto 
  

			
	WILLIAM BLAIR & COMPANY, L.L.C.
		
	By: 	 	/s/ Scott Patterson
		 	Name: Scott Patterson
		 	Title:   Principal
		
	By: 	 	 
		 	Name:
		 	Title:
	
	STIFEL, NICOLAUS & COMPANY, INCORPORATED
		
	By: 	 	/s/ Thomas K. Peltier
		 	Name: Thomas K. Peltier
		 	Title:   Managing Director
		
	By: 	 	 
		 	Name:
		 	Title:










 SCHEDULE A 
  

			
	 Underwriter
	  	Number of
Firm Shares
	 William Blair & Company, L.L.C.
	  	1,007,500
	 Stifel, Nicolaus & Company, Incorporated
	  	1,007,500
	 Canaccord Adams Inc.
	  	387,500
	 Stephens Inc.
	  	387,500
	 BB&T Capital Markets, a division of Scott & Stringfellow, LLC
	  	310,000
		  	 
	 Total
	  	3,100,000
		  	 

  

 Sch. A-1 








 SCHEDULE B 
 Permitted Free Writing Prospectuses 
 None. 
  

 Sch. B-1 








 EXHIBIT A-1 
 Lock-Up Agreement 
                     , 2009 
 William Blair & Company, L.L.C. 
 Stifel, Nicolaus & Company, Incorporated 
 As representatives of the Underwriters 
 named in Schedule A annexed to the 
 Underwriting Agreement referred to below

  

	c/o	William Blair & Company, L.L.C. 

 222 West Adams Street 
 Chicago, Illinois 60606 
 Ladies and Gentlemen: 
 This Lock-Up Agreement is being delivered to you in
connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) to be entered into by ICF International, Inc., a Delaware corporation (the “Company”), and you and the other underwriters named in
Schedule A annexed to the Underwriting Agreement, with respect to the public offering (the “Offering”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”). 
 In order to induce you to enter into the Underwriting Agreement, the undersigned agrees that, for a period (the “Lock-Up
Period”) beginning on the date hereof and ending on, and including, the date that is 60 days after the date of the final prospectus supplement relating to the Offering, the undersigned will not, without the prior written consent of either
William Blair & Company, L.L.C. or Stifel, Nicolaus & Company, Incorporated, (i) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of,
directly or indirectly, or file (or participate in the filing of) a registration statement with the Securities and Exchange Commission (the “Commission”) in respect of, or establish or increase a put equivalent position or liquidate
or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder (the “Exchange Act”) with
respect to, any Common Stock or any other securities of the Company that are substantially similar to Common Stock, or any securities convertible into or exchangeable or exercisable for, or any warrants or other rights to purchase, the foregoing,
(ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of Common Stock or any other securities of the Company that are substantially similar to Common Stock,
or any securities convertible into or exchangeable or exercisable for, or any warrants or other rights to purchase, the foregoing, whether any such transaction is to be settled by delivery of Common Stock or such other securities, in cash or
otherwise or (iii) publicly announce an intention to effect any transaction specified in clause (i) or (ii). The foregoing sentence shall not apply to (a) the registration of the offer and sale of Common Stock as contemplated by the
Underwriting Agreement and the sale of the Common Stock to the Underwriters (as defined in the Underwriting Agreement) in the Offering, (b) bona fide gifts, provided the recipient thereof agrees in writing with the Underwriters to be bound by
the terms of this Lock-Up Agreement, (c)

  

 Ex. A-1-1 








 
dispositions to any trust for the direct or indirect benefit of the undersigned and/or the immediate family of the undersigned, provided that such trust agrees in writing with the Underwriters to
be bound by the terms of this Lock-Up Agreement, (d) the exercise of outstanding vested options, provided that the recipient thereof does not sell such issued shares for the duration of this Lock-Up Agreement, and (e) dispositions of
Common Stock pursuant to agreements or plans in accordance with the guidelines specified by Rule 10b5-1 under the Exchange Act with an independent broker-dealer in effect as of the date of this Lock-Up Agreement. For purposes of this paragraph,
“immediate family” shall mean the undersigned and the spouse, any lineal descendent, father, mother, brother or sister of the undersigned. 
 In addition, the undersigned hereby waives any rights the undersigned may have to require registration of Common Stock in connection with the filing of a registration statement relating to the Offering.
The undersigned further agrees that, for the Lock-Up Period, the undersigned will not, without the prior written consent of either William Blair & Company, L.L.C. or Stifel, Nicolaus & Company, Incorporated, make any demand for, or
exercise any right with respect to, the registration of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or warrants or other rights to purchase Common Stock or any such securities. 
 Notwithstanding the above, if (a) during the period that begins on the date that is fifteen (15) calendar days plus three
(3) business days before the last day of the Lock-Up Period and ends on the last day of the Lock-Up Period, the Company issues an earnings release or material news or a material event relating to the Company occurs; or (b) prior to the
expiration of the Lock-Up Period, the Company announces that it will release earnings results during the sixteen (16) day period beginning on the last day of the Lock-Up Period, then the restrictions imposed by this Lock-Up Agreement shall
continue to apply until the expiration of the date that is fifteen (15) calendar days plus three (3) business days after the date on which the issuance of the earnings release or the material news or material event occurs (the
“Extended Period”), except that the restrictions imposed by this Lock-Up Agreement shall not continue to apply during the Extended Period so long as the Company meets the registrant requirements set forth in Rule 139 under the Act
for the publishing of issuer-specific research reports. 
 In addition, the undersigned hereby waives any and all preemptive
rights, participation rights, resale rights, rights of first refusal and similar rights that the undersigned may have in connection with the Offering or with any issuance or sale by the Company of any equity or other securities before the Offering,
except for any such rights as have been heretofore duly exercised. 
 The undersigned hereby confirms that the undersigned has
not, directly or indirectly, taken, and hereby covenants that the undersigned will not, directly or indirectly, take, any action designed, or which has constituted or will constitute or might reasonably be expected to cause or result in the
stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of shares of Common Stock. 
 *     *     * 
  

 Ex. A-1-2 








 If (i) the Company notifies you in writing that it does not intend to proceed with the
Offering, (ii) the registration statement filed with the Commission with respect to the Offering is withdrawn or (iii) for any reason the Underwriting Agreement shall be terminated prior to the “time of purchase” (as defined in
the Underwriting Agreement), this Lock-Up Agreement shall be terminated and the undersigned shall be released from its obligations hereunder. 
  

	
	Very truly yours,
	
	  
	Name:


  

 Ex. A-1-3 








 EXHIBIT A-2 
 Lock-Up Agreement 
                     , 2009 
 William Blair & Company, L.L.C. 
 Stifel, Nicolaus & Company, Incorporated 
 As representatives of the Underwriters 
 named in Schedule A annexed to the 
 Underwriting Agreement referred to below

  

	c/o	William Blair & Company, L.L.C. 

 222 West Adams Street 
 Chicago, Illinois 60606 
 Ladies and Gentlemen: 
 This Lock-Up Agreement is being delivered to you in
connection with the proposed Underwriting Agreement (the “Underwriting Agreement”) to be entered into by ICF International, Inc., a Delaware corporation (the “Company”), and you and the other underwriters named in
Schedule A annexed to the Underwriting Agreement, with respect to the public offering (the “Offering”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”). 
 In order to induce you to enter into the Underwriting Agreement, the undersigned agrees that, for a period (the “Lock-Up
Period”) beginning on the date hereof and ending on, and including, the date that is 45 days after the date of the final prospectus supplement relating to the Offering, the undersigned will not, without the prior written consent of either
William Blair & Company, L.L.C. or Stifel, Nicolaus & Company, Incorporated, (i) sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any option to purchase or otherwise dispose of or agree to dispose of,
directly or indirectly, or file (or participate in the filing of) a registration statement with the Securities and Exchange Commission (the “Commission”) in respect of, or establish or increase a put equivalent position or liquidate
or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission promulgated thereunder (the “Exchange Act”) with
respect to, any Common Stock or any other securities of the Company that are substantially similar to Common Stock, or any securities convertible into or exchangeable or exercisable for, or any warrants or other rights to purchase, the foregoing,
(ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of Common Stock or any other securities of the Company that are substantially similar to Common Stock,
or any securities convertible into or exchangeable or exercisable for, or any warrants or other rights to purchase, the foregoing, whether any such transaction is to be settled by delivery of Common Stock or such other securities, in cash or
otherwise or (iii) publicly announce an intention to effect any transaction specified in clause (i) or (ii). The foregoing sentence shall not apply to (a) the registration of the offer and sale of Common Stock as contemplated by the
Underwriting Agreement and the sale of the Common Stock to the Underwriters (as defined in

  

 Ex. A-2-1 








 
the Underwriting Agreement) in the Offering, (b) bona fide gifts, provided the recipient thereof agrees in writing with the Underwriters to be bound by the terms of this Lock-Up Agreement,
(c) dispositions to any trust for the direct or indirect benefit of the undersigned and/or the immediate family of the undersigned, provided that such trust agrees in writing with the Underwriters to be bound by the terms of this Lock-Up
Agreement, and (d) the exercise of outstanding vested options, provided that the recipient thereof does not sell such issued shares for the duration of this Lock-Up Agreement. For purposes of this paragraph, “immediate family” shall
mean the undersigned and the spouse, any lineal descendent, father, mother, brother or sister of the undersigned. 
 In
addition, the undersigned hereby waives any rights the undersigned may have to require registration of Common Stock in connection with the filing of a registration statement relating to the Offering. The undersigned further agrees that, for the
Lock-Up Period, the undersigned will not, without the prior written consent of either William Blair & Company, L.L.C. or Stifel, Nicolaus & Company, Incorporated, make any demand for, or exercise any right with respect to, the
registration of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, or warrants or other rights to purchase Common Stock or any such securities. 
 Notwithstanding the above, if (a) during the period that begins on the date that is fifteen (15) calendar days plus three
(3) business days before the last day of the Lock-Up Period and ends on the last day of the Lock-Up Period, the Company issues an earnings release or material news or a material event relating to the Company occurs; or (b) prior to the
expiration of the Lock-Up Period, the Company announces that it will release earnings results during the sixteen (16) day period beginning on the last day of the Lock-Up Period, then the restrictions imposed by this Lock-Up Agreement shall
continue to apply until the expiration of the date that is fifteen (15) calendar days plus three (3) business days after the date on which the issuance of the earnings release or the material news or material event occurs (the
“Extended Period”), except that the restrictions imposed by this Lock-Up Agreement shall not continue to apply during the Extended Period so long as the Company meets the registrant requirements set forth in Rule 139 under the Act
for the publishing of issuer-specific research reports. 
 In addition, the undersigned hereby waives any and all preemptive
rights, participation rights, resale rights, rights of first refusal and similar rights that the undersigned may have in connection with the Offering or with any issuance or sale by the Company of any equity or other securities before the Offering,
except for any such rights as have been heretofore duly exercised. 
 The undersigned hereby confirms that the undersigned has
not, directly or indirectly, taken, and hereby covenants that the undersigned will not, directly or indirectly, take, any action designed, or which has constituted or will constitute or might reasonably be expected to cause or result in the
stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of shares of Common Stock. 
 *     *     * 
  

 Ex. A-2-2 








 If (i) the Company notifies you in writing that it does not intend to proceed with the
Offering, (ii) the registration statement filed with the Commission with respect to the Offering is withdrawn or (iii) for any reason the Underwriting Agreement shall be terminated prior to the “time of purchase” (as defined in
the Underwriting Agreement), this Lock-Up Agreement shall be terminated and the undersigned shall be released from its obligations hereunder. 
  

	
	Very truly yours,
	
	  
	Name:


  

 Ex. A-2-3 








 EXHIBIT A-3 
 LIST OF PARTIES TO EXECUTE LOCK-UP AGREEMENTS 
  

			
	 Officers and Directors
	 	 Position

	 1.      Sudhakar Kesavan
	 	Chairman, President and Chief Executive Officer
		
	 2.      John Wasson
	 	Executive Vice President and Chief Operating Officer
		
	 3.      Alan Stewart
	 	Senior Vice President, Chief Financial Officer and Secretary
		
	 4.      Ellen Glover
	 	Executive Vice President
		
	 5.      Gerald Croan
	 	Executive Vice President
		
	 6.      Dr. Edward H. Bersoff
	 	Director
		
	 7.      Dr. Srikant M. Datar
	 	Director
		
	 8.      Joel R. Jacks
	 	Director
		
	 9.      David C. Lucien
	 	Director
		
	 10.    Peter M. Schulte
	 	Director
		
	 11.    Eileen O’Shea Auen
	 	Director
		
	 12.    Richard M. Feldt
	 	Director
		
	 Five Percent Stockholders
	 	 
	 1.      CM Equity Partners, L.P.
	 	
		
	 2.      CMEP Co-Investment ICF, L.P.
	 	
		
	 3.      CM Equity Partners II, L.P.
	 	
		
	 4.      CM Equity Partners II Co-Investors, L.P.
	 	

  

 Ex. A-3-1 








 EXHIBIT B 
 FORM OF OPINION OF SQUIRE, SANDERS & DEMPSEY L.L.P. 
  

	1.	The Company is a corporation validly existing and in good standing under the laws of the State of Delaware, with the requisite corporate power and authority to own,
lease and operate its properties and conduct its business as described in the Registration Statement, the Pre-Pricing Prospectus and the Prospectus, and to execute and deliver the Underwriting Agreement and perform its obligations thereunder,
including the issuance, sale and delivery of the Shares as contemplated by the Underwriting Agreement. 

  

	2.	Each of the Company’s Significant Subsidiaries is validly existing and in good standing as a corporation or limited liability company, as applicable, under the
laws of its jurisdiction of incorporation or formation, with the requisite power and authority (corporate or limited liability company, as applicable) to own, lease and operate its properties and to conduct its business as described in the
Registration Statement, the Pre-Pricing Prospectus and the Prospectus. 

  

	3.	The Company and the Significant Subsidiaries are each duly qualified to do business as a foreign corporation or limited liability company, as applicable, and are in
good standing in each jurisdiction where the ownership or leasing of their respective properties or the conduct of their respective businesses requires such qualification, except where the failure to be so qualified and in good standing would not,
individually or in the aggregate, have a Material Adverse Effect. 

  

	4.	The Underwriting Agreement has been duly authorized, executed and delivered by the Company. 

  

	5.	The Shares have been duly authorized and, when issued and delivered against payment therefor in accordance with the Underwriting Agreement, will be validly issued,
fully paid and nonassessable, and will be free of statutory preemptive rights and, to our knowledge, contractual preemptive rights, resale rights, rights of first refusal and similar rights. 

  

	6.	The Company has an authorized and outstanding capitalization as set forth in the Registration Statement, the Pre-Pricing Prospectus and the Prospectus; all of the
issued and outstanding shares of capital stock of the Company have been duly authorized and validly issued, are to our knowledge fully paid and nonassessable, and are free of statutory preemptive rights and, to our knowledge, contractual preemptive
rights, resale rights, rights of first refusal and similar rights. 

  

	7.	The Amended and Restated Certificate of Incorporation of the Company and the Amended and Restated Bylaws of the Company, each in the form filed as an exhibit to the
Registration Statement, have been duly adopted and are in full force and effect as of the date hereof, in each case in accordance with the Delaware General Corporation Law, and the Amended and Restated Certificate of Incorporation has been filed as
required with the Secretary of State of Delaware. 

  

 Ex. B-1 









	8.	All of the outstanding shares of capital stock of each of the Significant Subsidiaries have been duly authorized and are validly issued, fully paid and nonassessable
and, except as otherwise disclosed in the Registration Statement (excluding the exhibits thereto), the Pre-Pricing Prospectus and the Prospectus, are owned by the Company, in each case subject to no security interest, other encumbrance or adverse
claim. 

  

	9.	The Shares are duly listed and authorized for trading, subject to official notice of issuance, on The NASDAQ Stock Market. 

  

	10.	The capital stock of the Company, including the Shares, conforms in all material respects to the description thereof contained in the Registration Statement, the
Pre-Pricing Prospectus and the Prospectus. 

  

	11.	The Registration Statement, the Pre-Pricing Prospectus and the Prospectus, including the Incorporated Documents (except as to the financial statements and schedules,
and other financial data derived therefrom, contained or incorporated by reference therein, as to which we express no opinion), at their respective effective or issue dates and in the case of each of the Incorporated Documents, at the time such
document was filed with the Commission, complied as to form in all material respects with the requirements of the Act or the Exchange Act, as applicable (including, in the case of the Prospectus, Section 10(a) of the Act); the eligibility
requirements for the use of Form S-3 in connection with the registration of the Shares were met at the time of filing the Registration Statement; and the Registration Statement meets, and the offering and sale of the Shares as contemplated by the
Underwriting Agreement complies with, the requirements of Rule 415 under the Act (including, without limitation, Rule 415(a)(5) under the Act). 

  

	12.	To our knowledge, the Company is not an “ineligible issuer” (as defined in Rule 405 under the Act) as of the eligibility determination date for purposes of
Rules 164 and 433 under the Act with respect to the offering of the Shares contemplated by the Registration Statement. 

  

	13.	The Registration Statement has become effective under the Act and, to our knowledge, no stop order proceedings with respect thereto are pending or threatened under the
Act, and any required filing of the Prospectus pursuant to Rule 424 under the Act has been made in the manner and within the time period required by such Rule 424 and in compliance with Rule 430B and in the manner and within the time period required
by Rule 430A under the Act. 

  

	14.	 No approval, authorization, consent, order or filing under any federal law, the laws of the State of New York or the Commonwealth of Virginia or under
the Delaware General Corporation Law, or approval of the stockholders of the Company, is required in connection with the issuance and sale of the Shares or with the consummation by the Company of the transactions contemplated by the Underwriting
Agreement other than (a) registration of the Shares under the Act, which has been effected, (b) as may be required under the state securities or blue sky laws of the various jurisdictions in which the Shares are being offered by the
Underwriters, (c) as may be required in connection with the listing of the Shares on The NASDAQ Stock Market, and (d) as may be required under the Conduct Rules of the



  

 Ex. B-2 









	 	 
NASD, as enforced by the FINRA Board of Governors. 


  

	15.	The execution, delivery and performance of the Underwriting Agreement by the Company, the issuance and sale of the Shares and the consummation of the transactions
contemplated by the Underwriting Agreement do not and will not result in any breach or violation of or constitute a default under (nor constitute any event which, with notice, lapse of time or both, would result in any breach or violation of or
constitute a default under or give the holder of any indebtedness (or a person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a part of such indebtedness under) (or result in the creation
or imposition of a lien, charge or encumbrance on any property or assets of the Company or any Significant Subsidiary pursuant to) (i) the charter or bylaws of the Company or organizational documents of any of the Significant Subsidiaries, or
(ii) any indenture, mortgage, deed of trust, bank loan or credit agreement (except as disclosed in the Registration Statement, the Pre-Pricing Prospectus and the Prospectus as regards repayment obligations under the Company’s credit line)
or other evidence of indebtedness, or any license, lease, contract or other agreement or instrument (collectively, “Agreements and Instruments”) that is filed as an exhibit to the Registration Statement or any Incorporated Document or, to
our knowledge, under any other Agreement and Instrument to which the Company or any of the Significant Subsidiaries is a party or by which any of them or any of their respective properties may be bound or affected, or (iii) federal laws, the
laws of the State of New York or the Commonwealth of Virginia or the Delaware General Corporation Law, or (iv) any decree, judgment or order applicable to the Company or any of the Significant Subsidiaries or any of their respective properties,
which decree, judgment or order is known by us. 

  

	16.	To our knowledge, there are no contracts, licenses, agreements, leases or documents of a character that are required to be described in the Registration Statement, the
Pre-Pricing Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement or any Incorporated Document that have not been so described or filed as required. 

  

	17.	To our knowledge, (i) the Company is not a party to any legal or governmental action or proceeding that challenges the validity or enforceability, or seeks to
enjoin the performance, of the Underwriting Agreement; and (ii) there are no actions, suits, claims, investigations or proceedings pending, threatened or contemplated to which the Company or any of the Significant Subsidiaries or any of their
respective directors or officers is or would be a party or to which any of their respective properties is or would be subject at law or in equity, before or by any federal, state, local or foreign governmental or regulatory commission, board, body,
authority or agency that are required to be described in the Registration Statement, the Pre-Pricing Prospectus or the Prospectus but are not so described as required. 

  

	18.	The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Pre-Pricing
Prospectus and the Prospectus, will not be an “investment company” as such term is defined in the Investment Company Act. 

  

	19.	 The statements in the Pre-Pricing Prospectus and the Prospectus under the headings



  

 Ex. B-3 









	 	 
“Certain U.S. Federal Income Tax Considerations for Non-U.S. Holders” and “Description of Capital Stock,” insofar as such statements constitute summaries of documents or legal
proceedings or refer to matters of law or legal conclusions, fairly present and summarize such information in the context in which made in the Pre-Pricing Prospectus and the Prospectus. 


  

	20.	Except for the rights described in the Prospectus that have not been exercised, no person has the right, pursuant to the terms of any contract, agreement or other
instrument described in or filed as an exhibit to the Registration Statement or any Incorporated Document, or otherwise known to us, to cause the Company to register under the Act any shares of capital stock of the Company or to include any such
shares in the Registration Statement or the offering contemplated thereby. 

 We have participated in conferences
with officers and other representatives of the Company, representatives of the independent registered public accounting firm for the Company and representatives of the Underwriters and their counsel at which the contents of the Registration
Statement, the Pre-Pricing Prospectus, and the Prospectus were discussed. Although we have not independently verified and are not passing upon and do not assume responsibility for the accuracy, completeness or fairness of the statements contained in
the Registration Statement, the Pre-Pricing Prospectus, or the Prospectus (except as and to the extent stated in subparagraphs 6, 10 and 19 above), on the basis of the foregoing, nothing has come to our attention that causes us to believe that
(i) the Registration Statement, at the Effective Time, contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not misleading, (ii) the
Disclosure Package (as defined below), as of the Applicable Time (as defined below), when taken together with the Pricing Information (as defined below), contained an untrue statement of a material fact or omitted to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading or (iii) the Prospectus, as of its date, or as of the date hereof, contained or contains an untrue statement of a material
fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading (it being understood that we express no view with respect to the
financial statements and schedules, and other financial data derived therefrom, included or incorporated by reference into, or omitted from, the Registration Statement, the Disclosure Package or the Prospectus). As used in this paragraph,
(A) “Disclosure Package” means the Pre-Pricing Prospectus, (B) “Applicable Time” means [•] [A.M./.P.M.], New York City time, on [•], 2009, and (C) “Pricing Information”
means (i) the number of Shares offered for sale pursuant to the Prospectus and (ii) the public offering price per Share, in the case of each of clause (C)(i) and clause (C)(ii), as reflected on the cover page of the Prospectus Supplement.

 Capitalized terms used herein without definition shall have the respective meanings ascribed to them in the Underwriting
Agreement. 
  

 Ex. B-4 








 EXHIBIT C 
 OFFICERS’ CERTIFICATE 
 Each of the undersigned,
Sudhakar Kesavan, Chairman & Chief Executive Officer of ICF International, Inc., a Delaware corporation (the “Company”), and Alan Stewart, Chief Financial Officer of the Company, on behalf of the Company, does hereby
certify pursuant to Section 6(g) of that certain Underwriting Agreement dated December [•], 2009 (the “Underwriting Agreement”) among the Company and on behalf of the several Underwriters named therein, William
Blair & Company, L.L.C. and Stifel, Nicolaus & Company, Incorporated, that as of the date hereof: 
  

	1.	He has reviewed the Registration Statement, the Pre-Pricing Prospectus, the Prospectus and each Permitted Free Writing Prospectus. 

  

	2.	The representations and warranties of the Company as set forth in the Underwriting Agreement are true and correct as of the date hereof and as if made on the date
hereof. 

  

	3.	The Company has performed all of its obligations under the Underwriting Agreement as are to be performed at or before the date hereof. 

  

	4.	The conditions set forth in paragraph (f) of Section 6 of the Underwriting Agreement have been met. 

 Capitalized terms used herein without definition shall have the respective meanings ascribed to them in the Underwriting Agreement.

 IN WITNESS WHEREOF, the undersigned have hereunto set their hands on this
[•] day of December, 2009. 
  

			
	  
	Name: 	 	Sudhakar Kesavan
	Title:	 	Chairman & Chief Executive Officer
		
	  	 	  
	Name:	 	Alan Stewart
	Title:	 	Chief Financial Officer


  

 Ex. C-1